Cardio Diagnostics Holdings, Inc. CDIO
1.95
0.04
2.09%
as of 25 Sep
- Market cap
- $5.7M
- P/E
- 0.0×
Follow CDIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
446.18 | 318.47 | 331.71 | 443.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.06) | (3.48) | (3.55) | (4.83) | |
P/B ratio |
0.86 | 0.68 | 0.62 | 0.87 | |
Price to Tangible BV |
0.86 | 0.68 | 0.62 | 0.87 | |
EV/Sales |
43.95 | (24.52) | (92.06) | 61.27 | |
EV/EBITDA |
0.00 | 0.06 | 0.25 | 0.00 | |
EV/Operating CF |
(0.12) | 0.06 | 0.26 | (0.16) | |
EV/FCF |
(0.12) | 0.06 | 0.25 | (0.15) | |
Quick Ratio |
15.98 | 8.46 | 14.41 | 15.56 | |
Current Ratio |
17.39 | 9.79 | 15.76 | 17.15 | |
Net Debt/EBITDA |
3.92 | 3.73 | 4.19 | 3.98 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.93 | 0.87 | 0.89 | |
Capex/Depreciation |
(1.82) | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 9,552.78% | 4,807.41% | 3,016.67% | |
Selling, General and Administrative Expense of Revenue |
59,120.69% | 30,877.78% | 61,192.59% | 24,722.22% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
855.17% | 666.67% | 914.81% | 451.85% | |
Graham Net Nets |
0.89 | 1.08 | 1.28 | 0.87 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(72.61%) | (137.27%) | (173.33%) | (133.33%) | |
Free Cash Flow Yield |
(84.38%) | (124.63%) | (109.62%) | (89.86%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.79) | (0.78) | (0.55) | (0.45) | |
Capex per Share |
(0.09) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.89) | (0.78) | (0.55) | (0.45) | |
Cash per Share |
3.62 | 2.92 | 2.49 | 1.89 | |
Shareholders Equity per Share |
4.64 | 3.98 | 3.13 | 2.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.64 | 3.98 | 3.13 | 2.51 | |
Free Cash Flow |
(1.56) | (1.36) | (1.56) | (1.34) | |
Working Capital |
6.53 | 5.32 | 7.25 | 5.80 | |
Capital Expenditures |
(0.16) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
6.29 | 5.13 | 7.09 | 5.66 | |
EV/EBIT |
0.00 | 0.06 | 0.23 | 0.00 | |
Capex to Sales |
56.14 | 0.00 | 0.67 | 0.00 | |
Net Profit Margin |
(59,120.69%) | (40,705.56%) | (66,229.63%) | (27,805.56%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.01 | 0.01 | 0.01 | |
Average Payables |
0.11 | 0.09 | 0.12 | 0.09 | |
Average Assets |
6.64 | 9.19 | 10.92 | 9.16 | |
Average Common Equity |
5.92 | 8.27 | 10.14 | 8.58 |
Columns are period end dates